Cargando…

Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19

The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIF...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppeta, Luca, Somma, Giuseppina, Ferrari, Cristiana, Mazza, Andrea, Rizza, Stefano, Trabucco Aurilio, Marco, Perrone, Stefano, Magrini, Andrea, Pietroiusti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472926/
https://www.ncbi.nlm.nih.gov/pubmed/34579184
http://dx.doi.org/10.3390/vaccines9090947
_version_ 1784574859699814400
author Coppeta, Luca
Somma, Giuseppina
Ferrari, Cristiana
Mazza, Andrea
Rizza, Stefano
Trabucco Aurilio, Marco
Perrone, Stefano
Magrini, Andrea
Pietroiusti, Antonio
author_facet Coppeta, Luca
Somma, Giuseppina
Ferrari, Cristiana
Mazza, Andrea
Rizza, Stefano
Trabucco Aurilio, Marco
Perrone, Stefano
Magrini, Andrea
Pietroiusti, Antonio
author_sort Coppeta, Luca
collection PubMed
description The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators.
format Online
Article
Text
id pubmed-8472926
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84729262021-09-28 Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Coppeta, Luca Somma, Giuseppina Ferrari, Cristiana Mazza, Andrea Rizza, Stefano Trabucco Aurilio, Marco Perrone, Stefano Magrini, Andrea Pietroiusti, Antonio Vaccines (Basel) Article The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators. MDPI 2021-08-25 /pmc/articles/PMC8472926/ /pubmed/34579184 http://dx.doi.org/10.3390/vaccines9090947 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Coppeta, Luca
Somma, Giuseppina
Ferrari, Cristiana
Mazza, Andrea
Rizza, Stefano
Trabucco Aurilio, Marco
Perrone, Stefano
Magrini, Andrea
Pietroiusti, Antonio
Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
title Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
title_full Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
title_fullStr Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
title_full_unstemmed Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
title_short Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
title_sort persistence of anti-s titre among healthcare workers vaccinated with bnt162b2 mrna covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472926/
https://www.ncbi.nlm.nih.gov/pubmed/34579184
http://dx.doi.org/10.3390/vaccines9090947
work_keys_str_mv AT coppetaluca persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT sommagiuseppina persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT ferraricristiana persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT mazzaandrea persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT rizzastefano persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT trabuccoauriliomarco persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT perronestefano persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT magriniandrea persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19
AT pietroiustiantonio persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19